Recruitment

Recruitment Status
Completed
Estimated Enrollment
92

Exclusion Criteria

Co-infection with HIV or hepatitis B virus (HBV)
Chronic use of systemic immunosuppressive agents
Pregnant or nursing female or male with pregnant female partner
...
Co-infection with HIV or hepatitis B virus (HBV)
Chronic use of systemic immunosuppressive agents
Pregnant or nursing female or male with pregnant female partner
Presence of cirrhosis
History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol
Prior exposure to approved or experimental HCV Protease Inhibitors
Current or prior history of clinical hepatic decompensation

Summary

Conditions
Hepatitis C Virus Infection
Type
Interventional
Phase
Phase 1
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Double (Participant, Investigator)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 65 years
Gender
Both males and females

Exclusion Criteria

Co-infection with HIV or hepatitis B virus (HBV)
Chronic use of systemic immunosuppressive agents
Pregnant or nursing female or male with pregnant female partner
...
Co-infection with HIV or hepatitis B virus (HBV)
Chronic use of systemic immunosuppressive agents
Pregnant or nursing female or male with pregnant female partner
Presence of cirrhosis
History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol
Prior exposure to approved or experimental HCV Protease Inhibitors
Current or prior history of clinical hepatic decompensation

Locations

DeLand, Florida
San Juan
Marlton, New Jersey
Kansas City, Missouri
San Antonio, Texas
...
DeLand, Florida
San Juan
Marlton, New Jersey
Kansas City, Missouri
San Antonio, Texas
Knoxville, Tennessee
Berlin, New Jersey
Costa Mesa, California
Philadelphia, Pennsylvania
Saint Louis, Missouri
Orlando, Florida

Tracking Information

NCT #
NCT02185794
Collaborators
Not Provided
Investigators
Study Director: Gilead Study Director Gilead Sciences